Ring Is Alcohol Moiety Patents (Class 514/548)
-
Publication number: 20070197452Abstract: The invention provides compositions, methods and uses comprising a scyllo-inositol compound of the formula Ia or Ib or a compound of the formula Ia or Ib wherein one, two or three hydroxyl groups are replaced by substituents with retention of configuration, or pharmaceutically acceptable salts thereof, in a therapeutically effective amount to provide beneficial effects in the treatment of an amyloid-related disease.Type: ApplicationFiled: February 16, 2007Publication date: August 23, 2007Inventor: JoAnne McLaurin
-
Publication number: 20070197606Abstract: As described herein, L-FABP is an antioxidant and as such PPAR agonists such as the fibrate and statin class of pharmacological agents (e.g., clofibrate) can be used to induce FABP which in turn induces antioxidant activity. This anti-oxidant activity may be used to treat or prevent diseases characterized by free radical damage. These include but are by no means limited to cholestasis, cirrhosis, nonalcholic liver disease, fatty liver, drug-induced free radical damage (e.g., anticancer agents, acetaminophen overdose, etc.Type: ApplicationFiled: February 21, 2007Publication date: August 23, 2007Inventors: Frank J. Burczynski, GuQi Wang, Yuewen Gong
-
Publication number: 20070179194Abstract: The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.Type: ApplicationFiled: June 29, 2006Publication date: August 2, 2007Applicants: Kowa Co., Ltd., Nissan Chemical Industries, Ltd.Inventors: Taro Aoki, Katsutoshi Miyosawa
-
Publication number: 20070166375Abstract: Once a day modified release oral dosage form comprising of granules or pellets which are either compressed into tablet or filled inside the capsule, wherein the pellet has a core of active ingredient coated on non pareil seeds with a rate controlling functional coating of co-polymer of polyvinyl acetate optionally with an intermediate separating coating between the core and the functional coating layer.Type: ApplicationFiled: January 16, 2007Publication date: July 19, 2007Applicant: ASTRON RESEARCH LIMITEDInventors: Shashank Bababhai PATEL, Kamala Sultansingh YADAV, Jayant Kumar MANDAL, Kirti Bansidhar MAHESHWARI
-
Patent number: 7230030Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: GrantFiled: January 27, 2004Date of Patent: June 12, 2007Assignee: Schwarz Pharma AGInventors: Claus Meese, Bengt Sparf
-
Patent number: 7129231Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.Type: GrantFiled: February 22, 2002Date of Patent: October 31, 2006Assignee: The University of EdinburghInventors: Brian Robert Walker, Christopher Richard Watkin Edwards, Jonathan Robert Seckl
-
Patent number: 7122531Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.Type: GrantFiled: February 22, 2002Date of Patent: October 17, 2006Assignee: The University of EdinburghInventors: Brian Robert Walker, Christopher Richard Watkin Edwards, Jonathan Robert Seckl
-
Patent number: 7122532Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.Type: GrantFiled: February 22, 2002Date of Patent: October 17, 2006Assignee: The University of EdinburghInventors: Brian Robert Walker, Christopher Richard Watkin Edwards, Jonathan Robert Seckl
-
Patent number: 7056935Abstract: This invention relates to methods of using neurotrophic compounds having an affinity for FKBP-type immunophilins to stimulate or promote neuronal growth or regeneration and to prevent neuronal degeneration.Type: GrantFiled: March 14, 2001Date of Patent: June 6, 2006Assignee: GPI NIL Holdings, Inc.Inventors: Joseph P. Steiner, Gregory S. Hamilton
-
Patent number: 7034015Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.Type: GrantFiled: August 28, 2002Date of Patent: April 25, 2006Assignee: Leo Pharma A/SInventors: Erik Rytter Ottosen, Anne Marie Horneman, Xifu Liang
-
Patent number: 7026355Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.Type: GrantFiled: April 27, 2004Date of Patent: April 11, 2006Assignee: Transition Therapeutics Inc.Inventors: Tony Cruz, Aleksandra Pastrak
-
Patent number: 7001919Abstract: New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.Type: GrantFiled: December 14, 2000Date of Patent: February 21, 2006Assignee: Teva Gyogyszergyar ReszvenytarsasagInventors: Vilmos Keri, Csaba Szabo, Edit Nagyne Arvai, Judith Aronhime
-
Patent number: 6998422Abstract: Compositions having excellent blood lipid peroxide lowering activity are provided. In particular, compositions for lowering lipid peroxides in the blood which contain pravastatin together with at least one substance selected from the group consisting of taurine, pantethine and inositol hexanicotinate. Use of these compositions enables the provision of excellent preventive or remedial agents capable of lowering the concentration of lipid peroxides in the blood which show effects of injuring vascular endothelial cells, accelerating platelet aggregation, forming foam cells, etc.Type: GrantFiled: May 2, 2003Date of Patent: February 14, 2006Assignee: Sankyo Company, LimitedInventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
-
Patent number: 6994866Abstract: The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing (a) cyclic ketoenols having the formula ?in which the groups W, X, Y, Z, A, B, D, and G have the meanings given in the disclosure, and (b) the active compounds (1) to (23) listed in the disclosure. maintaining device useful in producing polyurethane foams.Type: GrantFiled: June 18, 2001Date of Patent: February 7, 2006Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Christoph Erdelen
-
Patent number: 6992106Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.Type: GrantFiled: June 12, 2002Date of Patent: January 31, 2006Assignee: Ajinomoto Co., Inc.Inventors: Yoshihiro Morinaga, Yukio Nihei, Yasuyo Suga, Manabu Suzuki, Kazuo Ohishi, Akira Okano
-
Patent number: 6974834Abstract: This invention relates to a process for the synthesis of enantiomerically enriched (1S,4R) 1-acetoxy-4-hydroxycyclopent-2-ene of Formula I, a compound useful as an intermediate in the synthesis of prostaglandins and prostanoids.Type: GrantFiled: January 7, 2004Date of Patent: December 13, 2005Assignee: Agouron Pharmaceuticals Inc.Inventor: Kevin Edward Henegar
-
Patent number: 6967218Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: GrantFiled: January 10, 2003Date of Patent: November 22, 2005Assignee: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Patent number: 6946487Abstract: This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active from may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.Type: GrantFiled: January 30, 2002Date of Patent: September 20, 2005Assignee: University of EdinburghInventors: Brian Robert Walker, Christopher Richard Watkin Edwards, Jonathan Robert Seckl
-
Patent number: 6916849Abstract: The present invention relates to compositions for lowering the total amount of cholesterol in the blood and methods of using the compositions. The compositions are a mixture of pravastatin and one or more vitamins selected from riboflavins, d-?-tocopherols, ascorbic acids and inositol hexanicotinate.Type: GrantFiled: May 1, 2003Date of Patent: July 12, 2005Assignee: Sankyo Company, LimitedInventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
-
Patent number: 6911472Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.Type: GrantFiled: May 3, 2002Date of Patent: June 28, 2005Assignee: Sandoz AGInventors: Deepak Hegde, Sushrut Kulkarni
-
Patent number: 6903076Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: November 26, 2003Date of Patent: June 7, 2005Assignees: Board of Trustees of Michigan State University, The Regents of the University of CaliforniaInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Patent number: 6903052Abstract: The invention concerns the use of certain compounds related to fatty acids to control nematodes that infest plants or the situs of plants. Nematodes that parasitize animals can also be controlled using the methods and composition of this invention. Certain of the useful compounds are fatty acid esters that are predicted inhibitors of nematode delta-12 fatty acid desaturases and can be, for example, from C16 to C20 in length.Type: GrantFiled: July 1, 2002Date of Patent: June 7, 2005Assignee: Divergence, Inc.Inventors: Deryck J. Williams, Andrew P. Kloek, Michelle Coutu Hresko
-
Patent number: 6890941Abstract: The present invention provides pharmaceutical compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, hypercholesterolemia, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, cholesterol gallstones, and lipid storage diseases. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising atherapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, and compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate. A typical pharmaceutical composition of the invention contains and effective amount of atorvastatin and an effective amount of policosanol.Type: GrantFiled: December 3, 2003Date of Patent: May 10, 2005Assignee: Procaps S.A.Inventors: Isaac A. Angres, Ruben Minski, Meyer Minski
-
Patent number: 6875746Abstract: Anthraquinones are described which have anticancer or antitumor activity and which are useful for inhibiting cancer cells and cells comprising tumors in vitro or in vivo. Preferably, the anthraquinones have the chemical formula: wherein R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R2 is a group containing 1-12 carbons selected from the group consisting of alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate and combinations thereof; and R3 is a group containing 1 to 12 carbons selected from the group consisting of methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, and combinations thereof.Type: GrantFiled: January 31, 2003Date of Patent: April 5, 2005Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Robert H. Cichewicz, Navindra P. Seeram, Yanjun Zhang
-
Patent number: 6872748Abstract: The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions that have such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for preventing, alleviating or treating pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neutopathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease or urgent urinary incontinence.Type: GrantFiled: December 18, 2002Date of Patent: March 29, 2005Assignee: Digital Biotech Co., Ltd.Inventor: Jee Woo Lee
-
Patent number: 6858650Abstract: The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(?)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.Type: GrantFiled: November 15, 2000Date of Patent: February 22, 2005Assignee: Schwarz Pharma AGInventor: Claus Meese
-
Patent number: 6858649Abstract: The selective potentiation and/or inhibition of the 5-HT2A and/or 5-HT1A response to serotonin (5-HT) is achieved using analogs of oleamide. Selective potentiation and/or inhibition of the 5-HT2A and/or 5-HT1A leads to a modulation of serotonergic signal transduction of cells having various receptor subtypes. A subset of analogs is identified that inhibits rather than potentiates the 5-HT2A, but not the 5-HT1A, receptor response. These analogs enable the selective modulation of serotonin receptor subtypes and even have opposing effects on the different subtypes. An analysis of the activity of the oleamide analogs discloses that the structural features required for activity are highly selective. In particular, the presence, position, and stereochemistry of the 9-cis double bond is required and even subtle structural variations reduce or eliminate activity.Type: GrantFiled: April 30, 1998Date of Patent: February 22, 2005Assignee: The Scripps Research InstituteInventor: Dale L. Boger
-
Patent number: 6844320Abstract: Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI2-mimetic, a thromboxane (TXA2) inhibitor, a compound possessing TXA2-agonistic and TXA2-inhibiting properties, a compound possessing TXA2-antagonistic and PGI2-memetic activities, and a TXA2 antagonist.Type: GrantFiled: July 24, 1998Date of Patent: January 18, 2005Assignees: Board of Regents, The University of Texas System, Schering AktiengesellschaftInventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampalli
-
Patent number: 6838443Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: November 26, 2003Date of Patent: January 4, 2005Assignees: Board of Trustees of Michigan State University, The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Publication number: 20040259886Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.Type: ApplicationFiled: May 6, 2004Publication date: December 23, 2004Applicant: Pfizer IncInventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
-
Publication number: 20040254238Abstract: Methods and compositions provided herein relate to the promotion of bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Disclosed is a method of enhancing bone formation by administering at least two components selected from at least one statin-like compound, at least one nitric oxide generating system, and at least one phosphodiesterase inhibitor. Also disclosed is a pharmaceutical composition comprising said at least two components.Type: ApplicationFiled: April 7, 2004Publication date: December 16, 2004Applicant: OSTEOSCREENInventors: I. Ross Garrett, Gregory R. Mundy, Gloria Gutierrez
-
Publication number: 20040248972Abstract: The invention provides derivatives of statin compounds, preferably with reduced, or unappreciable, inhibitory activity against HMG-CoA reductase as well as compositions comprising such compounds. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the non-statin compounds of the invention are also provided.Type: ApplicationFiled: May 17, 2004Publication date: December 9, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta
-
Publication number: 20040235935Abstract: Oral stable liquid pharmaceutical compositions comprising at least a statin derivative suspended in at least an oily excipient. The said composition allows to obtain a high bioavailability of the drug after oral administration to mammals. A process for manufacturing the said compositions.Type: ApplicationFiled: June 8, 2004Publication date: November 25, 2004Inventors: Francis Vanderbist, Antonio Sereno, Philippe Baudier
-
Publication number: 20040213782Abstract: The present invention provides compositions and methods for lowering intraocular pressure in a subject. More particularly, the invention provides a combination therapy for the treatment of an ophthalmic disorder mediated by an elevated intraocular pressure comprising administering to a subject an aquaporin modulating agent in combination with an aqueous humor modulating agent, where the aqueous humor modulating agent lowers intraocular pressure by a pathway other than the modulation of aquaporin.Type: ApplicationFiled: January 30, 2004Publication date: October 28, 2004Applicant: Pharmacia CorporationInventor: Martin B. Wax
-
Publication number: 20040209336Abstract: Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells.Type: ApplicationFiled: May 3, 2004Publication date: October 21, 2004Inventors: Chaitan Khosla, Peter Licari, John Carney
-
Publication number: 20040204387Abstract: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.Type: ApplicationFiled: February 26, 2004Publication date: October 14, 2004Inventor: JoAnne McLaurin
-
Publication number: 20040204485Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.Type: ApplicationFiled: January 13, 2004Publication date: October 14, 2004Inventors: James A. Sikorski, M. David Weingarten
-
Publication number: 20040198646Abstract: The present invention relates to compositions comprising solutions of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compositions.Type: ApplicationFiled: February 17, 2004Publication date: October 7, 2004Inventors: Moshe Flashner-Barak, E. Itzhak Lerner, Vered Rosenberger, Naomi Moldavski
-
Publication number: 20040198817Abstract: Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.Type: ApplicationFiled: April 20, 2004Publication date: October 7, 2004Inventors: Peter G. Klimko, John E. Bishop, Verney L. Sallee, Paul W. Zinke, George E. Barnes, Michael L. Chandler, Thomas R. Dean, Jesse A. May, Louis Desantis
-
Patent number: 6800615Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: December 12, 2002Date of Patent: October 5, 2004Assignees: Board of Trustees of Michigan State University, The Regent of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Patent number: 6797727Abstract: The present invention relates to the use of rhein or diacerhein compounds to treat and prevent vascular diseases that cause obstruction of the vascular system such as blood vessel restenosis and atherosclerosis.Type: GrantFiled: July 15, 2002Date of Patent: September 28, 2004Assignee: Transition Therapeutics Inc.Inventors: Tony Cruz, Aleksandra Pastrak
-
Publication number: 20040186046Abstract: The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 12, 2004Publication date: September 23, 2004Applicant: Pfizer IncInventors: Gillian Munro Burgess, Earl Michael Gibbs, Christopher Peter Wayman
-
Publication number: 20040186163Abstract: A combination product which comprises as pharmaceutically active ingredient at least one active ingredient component A and at least one active ingredient component B is described, where active ingredient component A is a direct soluble guanylate cyclase stimulator and active ingredient component B is a lipid-lowering agent.Type: ApplicationFiled: February 10, 2004Publication date: September 23, 2004Inventors: Hilmar Bischoff, Johannes-Peter Stasch
-
Publication number: 20040185102Abstract: A dosage form comprises (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a neutral or neutralized acidic polymer and (2) an HMG-CoA reductase inhibitor. The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor.Type: ApplicationFiled: December 18, 2003Publication date: September 23, 2004Applicant: Pfizer IncInventors: Dwayne T. Friesen, David K. Lyon, Douglas A. Lorenz, Rodney J. Ketner, Bruno C. Hancock, Timothy J. McDermott, Ravi M. Shanker
-
Publication number: 20040186164Abstract: Vessels are treated with a mixture of L-arginine and an agent which enhances the biotransformation of L-arginine into NO. The incidents associated with restenosis are expected to be substantially reduced and prevented providing for a reduced incidence of restenosis as a result of the injury.Type: ApplicationFiled: January 23, 2004Publication date: September 23, 2004Inventor: Wayne H. Kaesemeyer
-
Publication number: 20040186162Abstract: A process for the preparation of amorphous HMG-CoA reductase inhibitor and its hydrates thereof of desired particle size, which comprises: (a) dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent; (b) removing the solvent by freeze-drying.Type: ApplicationFiled: January 12, 2004Publication date: September 23, 2004Inventors: Acharya Poornaprajna, Joy Mathew, Ravindra Chandrappa, Madhavan Sridharan, Sambasivam Ganesh
-
Publication number: 20040176393Abstract: The invention is a pharmaceutical composition comprising an MMP inhibitor and a statin, said composition being useful for treating vascular diseases.Type: ApplicationFiled: April 22, 2003Publication date: September 9, 2004Inventors: Roger Schofield Newton, Bruce David Roth
-
Publication number: 20040167085Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.Type: ApplicationFiled: April 13, 2004Publication date: August 26, 2004Inventors: Deepak Hedge, Sushrut Kulkarni
-
Publication number: 20040146503Abstract: The invention relates to immunotherapy, and more specifically, to the use of a novel combination of immunological agents to induce stable immune tolerance to donor or host antigens in recipients of donor organs, tissues and cells.Type: ApplicationFiled: August 28, 2003Publication date: July 29, 2004Inventors: Raymond J. Tesi, Roland Buelow
-
2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
Patent number: RE39072Abstract: The present invention relates to a compound of the general formula wherein R1, R2, R3 and R4 are each a hydrogen or an acyl, a pharmaceutically acceptable acid addition salt thereof or a hydrate thereof; a pharmaceutical comprising this compound; a pharmaceutical composition comprising this compound and a pharmaceutically acceptable carrier; and 2-amino-2-(2-(4-(1-hydroxy-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol or 2-amino-2-(2-(4-formylphenyl)ethyl)propane-1,3-diol, the derivatives of the two compounds whose amino group and/or hydroxy group are(is) protected or a salt thereof. The compound of the present invention shows superior immunosuppressive action with less toxicity and higher safety, and is useful as a drug for prevention or suppression of rejection of organs or bone marrow transplantation, or as a drug for prevention or treatment of various autoimmune diseases or allergic diseases.Type: GrantFiled: April 3, 1998Date of Patent: April 18, 2006Assignee: Mitsubishi Pharma CorporationInventors: Kunitomo Adachi, Yoshiyuki Aoki, Tokushi Hanano, Koji Teshima, Yukio Hoshino, Tetsuro Fujita